Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
In the latest session, Cytokinetics Inc (NASDAQ: CYTK) closed at $64.66 up 1.81% from its previous closing price of $63.51. In other words, the price has increased by $1.81 from its previous closing price. On the day, 2.22 million shares were traded. CYTK stock price reached its highest trading level at $65.5 during the session, while it also had its lowest trading level at $63.59.
Ratios:
For a deeper understanding of Cytokinetics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.88 and its Current Ratio is at 6.88.
On April 24, 2025, Barclays started tracking the stock assigning a Overweight rating and target price of $55.
On February 07, 2025, Citigroup started tracking the stock assigning a Buy rating and target price of $86.Citigroup initiated its Buy rating on February 07, 2025, with a $86 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 02 ’25 when HENDERSON JOHN T sold 8,750 shares for $63.90 per share. The transaction valued at 559,125 led to the insider holds 74,578 shares of the business.
Malik Fady Ibraham sold 2,200 shares of CYTK for $140,558 on Dec 02 ’25. The EVP Research & Development now owns 140,610 shares after completing the transaction at $63.89 per share. On Dec 02 ’25, another insider, JOHN T HENDERSON, who serves as the Director of the company, bought 8,750 shares for $66.05 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CYTK now has a Market Capitalization of 7905650688 and an Enterprise Value of 8293368320. For the stock, the TTM Price-to-Sale (P/S) ratio is 90.65. Its current Enterprise Value per Revenue stands at 95.095 whereas that against EBITDA is -14.723.
Stock Price History:
The Beta on a monthly basis for CYTK is 0.56, which has changed by 0.26011908 over the last 52 weeks, in comparison to a change of 0.12415576 over the same period for the S&P500. Over the past 52 weeks, CYTK has reached a high of $69.33, while it has fallen to a 52-week low of $29.31. The 50-Day Moving Average of the stock is 6.26%, while the 200-Day Moving Average is calculated to be 45.60%.
Shares Statistics:
For the past three months, CYTK has traded an average of 2.14M shares per day and 1695040 over the past ten days. A total of 122.12M shares are outstanding, with a floating share count of 119.84M. Insiders hold about 1.98% of the company’s shares, while institutions hold 115.56% stake in the company. Shares short for CYTK as of 1763078400 were 14382900 with a Short Ratio of 6.73, compared to 1760486400 on 14198078. Therefore, it implies a Short% of Shares Outstanding of 14382900 and a Short% of Float of 15.24.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 8.0 analysts currently analyzing and rating the stock of Cytokinetics Inc (CYTK).The consensus estimate for the next quarter is -$1.59, with high estimates of -$1.34 and low estimates of -$1.79.
Analysts are recommending an EPS of between -$4.95 and -$6.81 for the fiscal current year, implying an average EPS of -$5.97. EPS for the following year is -$5.98, with 9.0 analysts recommending between -$4.62 and -$7.21.
Revenue Estimates
For the next quarter, 17 analysts are estimating revenue of $19.5M. There is a high estimate of $48.91M for the next quarter, whereas the lowest estimate is $7M.
A total of 19 analysts have provided revenue estimates for CYTK’s current fiscal year. The highest revenue estimate was $153.83M, while the lowest revenue estimate was $70.28M, resulting in an average revenue estimate of $83.37M. In the same quarter a year ago, actual revenue was $18.47MBased on 17 analysts’ estimates, the company’s revenue will be $139.17M in the next fiscal year. The high estimate is $243M and the low estimate is $54.1M.
